Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch Lombarte, Oscar
  • Tarancón Diez, Laura
  • Pedreño Lopez, Nuria
  • Arenas Busto, Miguel
  • Alvaro, Tamara
  • Casado, Concepción
  • Olivares, Isabel
  • Vera, Mar
  • Rodríguez, Carmen
  • del Romero, Jorge
  • López Galíndez, Cecilio
  • Ruiz Mateos, Ezequiel
  • Prado, Julia G.
  • Pernas, María
Background Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. Results In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. Conclusions These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses., Instituto de Salud Carlos III | Ref. PI13/02269, Instituto de Salud Carlos III | Ref. PI17/00164, Instituto de Salud Carlos III | Ref. PI16/0684, Instituto de Salud Carlos III | Ref. PI19/01127, Ministerio de Economía y Competitividad | Ref. RD12/0017/0028, Ministerio de Economía y Competitividad | Ref. RD16/0025/0020, Generalitat de Catalunya | Ref. AGAUR-FI_B 00582, Agencia Estatal de Investigación | Ref. RYC-2015-18241, Agencia Estatal de Investigación | Ref. PID2019-107931GA-I00, Xunta de Galicia | Ref. ED431F 2018/08, Ministerio de Economía y Competitividad | Ref. RD16/0025/0041
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status

  • Ceausu, Andra
  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Peraire, Joaquim|||0000-0001-7808-5479
  • López-Dupla, M.
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Vidal-Gonzalez, J.
  • Perpiñán, C.
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Veloso, S.
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Ruiz-Mateos, E.
  • Mallolas Masferrer, Josep|||0000-0002-8365-141X
  • Vidal, Francisco|||0000-0001-8089-4945
  • Rull, A.
A relationship between polymorphisms in genes encoding interleukin 7 (IL-7) and its cellular receptor (IL-7R) and antiretroviral therapy (ART)-associated immune recovery in HIV subjects has been previously reported. However, details of this relationship remain unclear, and the association of these polymorphisms with circulating IL-7/IL-7R levels is scarce. Here, we explored whether IL-7/IL-7R axis was associated with quantitative CD4 T-cell recovery in HIV-infected subjects. IL-7/IL-7R polymorphisms were assessed by genotyping, and multiple inheritance models were used to estimate both, their association with low pre-ART CD4 T-cell counts and incomplete immune recovery status after 48 weeks of suppressive ART. Integrated data from genetic variants association and soluble plasma IL-7/IL-7R quantification suggest that IL-7/IL-7R genotype expression could alter the homeostatic balance between soluble and membrane-bound receptors. The haplotype analyses indicates that allele combinations impacts pre-ART circulating CD4 T-cell counts, immune recovery status and the absolute increment of CD4 T-cell counts. The knowledge about how IL-7/IL-7R axis is related to quantitative CD4 T-cell recovery and immune recovery status after initiating ART could be useful regarding T-cell reservoirs investigations in HIV subjects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes

  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Gutiérrez-Valencia, Alicia|||0000-0003-3445-1574
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martí, Anna
  • Gómez-Bertomeu, Frederic
  • Auguet, Teresa
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Benavent-Bofill, Clara
  • Boqué, Carme
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Mestre, Maria Teresa
  • Vidal, Francesc|||0000-0002-6692-6186
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Permanent control of HIV-1 pathogenesis in exceptional elite controllers, a model of spontaneous cure

  • Casado, Concepcion
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Pernas, María
  • Tarancon-Diez, Laura
  • Rodriguez, Carmen
  • Sanchez-Merino, Víctor
  • Vera, Mar|||0000-0002-3841-7747
  • Olivares, Isabel
  • De Pablo-Bernal, Rebeca
  • Merino-Mansilla, Alberto
  • Del Romero, Jorge
  • Lorenzo-Redondo, Ramon
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Salgado, Maria|||0000-0003-1551-7216
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Lopez-Galindez, Cecilio
Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control viral replication. However, natural virological suppression and absence of immune dysfunction are not always long-term sustained. We define exceptional EC (EEC) as HIV-1 subjects who maintain the EC characteristics without disease progression for more than 25 years. We analyzed three EEC, diagnosed between 1988 and 1992, who never showed signs of clinical disease progression in absence of any antiretroviral treatment. A comprehensive clinical, virological, and immunological study was performed. The individuals simultaneously exhibited ≥3 described host protective alleles, low levels of total HIV-1 DNA (<20 copies/10 6 CD4 + T-cells) without evidence of replication-competent viruses (<0.025 IUPM), consistent with high levels of defective genomes, strong cellular HIV-1-specific immune response, and a high poly-functionality index (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Tarancon-Diez, Laura
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Arenas, Miguel
  • Alvaro, Tamara
  • Casado, Concepcion
  • Olivares, Isabel
  • Vera, Mar|||0000-0002-3841-7747
  • Rodriguez, Carmen
  • Del Romero, Jorge
  • López-Galíndez, Cecilio|||0000-0002-2324-9584
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Prado, Julia G.|||0000-0002-5439-4645
  • Pernas, María
Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses. The online version contains supplementary material available at 10.1186/s12977-022-00591-7.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy

  • Rodríguez-Gallego, Esther|||0000-0002-6363-2510
  • Gómez, Josep|||0000-0002-0573-7621
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Ferrando-Martínez, Sara
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Veloso Esteban, Sergio|||0000-0001-7943-1169
  • López-Dupla, Miguel
  • Beltrán-Debón, Raúl|||0000-0001-9691-1906
  • Alba, Verónica|||0000-0002-5925-9573
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Castellano, Alfonso J.
  • Leal, Manuel
  • Pacheco, Yolanda M.|||0000-0002-9451-8083
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Gutiérrez, Félix|||0000-0002-9485-6867
  • Vidal, Francesc|||0000-0002-6692-6186
  • Rull, Anna|||0000-0002-8907-7754
Dyslipidemia in HIV-infected patients is unique and pathophysiologically associated with host factors, HIV itself and the use of antiretroviral therapy (ART). The use of nuclear magnetic resonance spectroscopy (NMR) provides additional data to conventional lipid measurements concerning the number of lipoprotein subclasses and particle sizes. To investigate the ability of lipoprotein profile, we used a circulating metabolomic approach in a cohort of 103 ART-naive HIV-infected patients, who were initiating non-nucleoside analogue transcriptase inhibitor (NNRTI)-based ART, and we subsequently followed up these patients for 36 months. Univariate and multivariate analyses were performed to evaluate the predictive power of NMR spectroscopy. VLDL-metabolism (including VLDL lipid concentrations, sizes, and particle numbers), total triglycerides and lactate levels resulted in good classifiers of dyslipidemia (AUC 0.903). Total particles/HDL-P ratio was significantly higher in ART-associated dyslipidemia compared to ART-normolipidemia (p = 0.001). Large VLDL-Ps were positively associated with both LDL-triglycerides (ρ 0.682, p < 0.001) and lactate concentrations (ρ 0.416, p < 0.001), the last one a marker of mitochondrial low oxidative capacity. Our data suggest that circulating metabolites have better predictive values for HIV/ART-related dyslipidemia onset than do the biochemical markers associated with conventional lipid measurements. NMR identifies changes in VLDL-P, lactate and LDL-TG as potential clinical markers of baseline HIV-dyslipidemia predisposition. Differences in circulating metabolomics, especially differences in particle size, are indicators of important derangements of mitochondrial function that are linked to ART-related dyslipidemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control

  • Masip, Jenifer|||0000-0002-9233-5195
  • Rallón, Norma|||0000-0002-4643-247X
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Resino, Salvador|||0000-0001-8783-0450
  • Benito, José Miguel|||0000-0002-7172-049X
  • Viladés, Consuelo|||0000-0002-2991-9593
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Alcami, Jose|||0000-0003-0023-7377
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Gómez-Bertomeu, Frederic
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • Oteo, José A.|||0000-0001-7080-6542
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Martí, Anna
  • Alba, Verónica|||0000-0002-5925-9573
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Long-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography-electrospray ionization-quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, α-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals.